![Johan A. van Zyl](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Profile
Johan A.
van Zyl served as a Director-Supervisory Board at Bac BV.
Prior to that, he worked as a Deal Manager at Stonehage Fleming Private Equity Ltd.
from 2001 to 2009.
He completed his undergraduate degree from the University of Stellenbosch.
Former positions of Johan A. van Zyl
Companies | Position | End |
---|---|---|
Stonehage Fleming Private Equity Ltd.
![]() Stonehage Fleming Private Equity Ltd. Investment ManagersFinance Stonehage Fleming Private Equity Ltd (Stonehage Fleming Private Equity) is a private equity subsidiary of Stonehage Fleming (UK) Ltd founded in 2000. The firm is headquartered in London, United Kingdom. | Private Equity Investor | 30/11/2009 |
BAC BV
![]() BAC BV Industrial MachineryProducer Manufacturing BAC BV discovers, develops and manufactures affinity ligands and affinity purification products for the biopharmaceutical market. Its CaptureSelect products are used for drug discovery up to manufacturing of biopharmaceuticals and are based on a proprietary platform technology, integrating affinity ligand discovery, manufacturing and immobilization of single domain antibodies derived from Camelids. The company was founded in 1995 and is headquartered in Amsterdam, the Netherlands. | Director/Board Member | - |
Training of Johan A. van Zyl
University of Stellenbosch | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 2 |
---|---|
Stonehage Fleming Private Equity Ltd.
![]() Stonehage Fleming Private Equity Ltd. Investment ManagersFinance Stonehage Fleming Private Equity Ltd (Stonehage Fleming Private Equity) is a private equity subsidiary of Stonehage Fleming (UK) Ltd founded in 2000. The firm is headquartered in London, United Kingdom. | Finance |
BAC BV
![]() BAC BV Industrial MachineryProducer Manufacturing BAC BV discovers, develops and manufactures affinity ligands and affinity purification products for the biopharmaceutical market. Its CaptureSelect products are used for drug discovery up to manufacturing of biopharmaceuticals and are based on a proprietary platform technology, integrating affinity ligand discovery, manufacturing and immobilization of single domain antibodies derived from Camelids. The company was founded in 1995 and is headquartered in Amsterdam, the Netherlands. | Producer Manufacturing |
- Stock Market
- Insiders
- Johan A. van Zyl